Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is a prospective, multi-center trial wherein each included subject will receive the experimental externally focused ultrasound renal denervation therapy. It will be conducted on a maximum of fifty patients who meet the inclusion and exclusion criteria and have signed the informed consent form. Safety is the primary endpoint of this study and will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation. Clinical utility is the secondary endpoint of this study and will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.
Condition or disease
Device: Kona Externally Focused Ultrasound Therapy
Safety: Incidence of Adverse Events through 52 week follow-up [ Time Frame: One Year ]
Safety will be assessed by incidence and evaluation of any serious adverse effects associated with the investigational procedure through the 52-week evaluation of bilateral treatment. Included in this assessment will be the proportion of subjects with any of the following outcomes: (1) death, or (2) medical morbidity, including but not limited to renal artery aneurysm, stenosis, significant deterioration of renal function, fistulae or ureteral stenosis.
Secondary Outcome Measures :
Decrease in Blood Pressure [ Time Frame: 12 and 24 weeks post therapy ]
Clinical utility will be evaluated by assessing pre and post therapy systolic and diastolic blood pressure.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subject is at least 18 years of age.
Subject has systolic blood pressure of 160 mmHg in average or greater.
Subject has refractory, stable hypertension despite being treated with at least three hypertensive drugs.
Subject has two functioning kidneys, defined as eGFR ≥ 45 ml/min.
Subject has at least one renal artery on each side which is greater than 4mm.
Subject has hydronephrosis as seen on MRA or ultrasound.
Subject has renal stenosis greater than 50% based on baseline MRA.
Subject has a renal stent or other implant in the region.
Subject has kidney stones which are symptomatic and/or greater than 1cm or in the discretion of the investigator may interfere with treatment.
Subject has a history of abdominal surgery within the past six months.
Subject has heterogeneities in the kidney such as large cysts or tumors which in the discretion of the investigator may interfere with treatment.
Subject has active pyelonephritis or a history of pyelonephritis which in the discretion of the investigator may interfere with treatment.
Subject has a history of myocardial infarction, unstable angina pectoris, or cerebrovascular accident within the last six months.
Subject has hemodynamically significant valvular heart disease.
Subject has an implantable cardioverter defibrillator, pacemaker, neurostimulator or other device incompatible with MRI.
Subject has a body weight > 150 kilograms.
Subject has a target treatment depth > 14 cm.
Subject is pregnant, nursing or intends to become pregnant during the trial period.
Subject is currently enrolled in other potentially confounding research.
Subject has any condition that, at the discretion of the investigator, would preclude participation in the trial.